DURHAM – Life sciences veteran executive J.D. Mowery is the new chief executive officer at KBI Biopharma and Selexis SA. He succeeds Tim Lowery who was named CEO on an interim basis last November.
Lowery is president of San Diego-based JSR Life Sciences, which owns Durham-based KBI and Selexis.
KBI and Selexis are CDMOS, or contract development and manufacturing organizations,
“Through decades of service, J.D. has devoted his career to meaningful work with a clear focus on patient impact through the launch of novel therapies and by providing world-class service to manufacturing and development partners,” Lowery said in Monday’s announcement. “As we enter a pivotal growth phase, J.D. will play a crucial role in leading KBI and Selexis and empowering our global teams to succeed through servant leadership. We are confident his commitment to our long-term impact will guide us to greater success.”
Mowery has worked for Genentech, Celgene, Juno, and Treadwell Therapeutics plus CDMOs Lonza and AGC Biologics.
